Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haploidentical stem cells
- Development stage
- Unknown
- Lead developer
- Weill Cornell Medicine
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Haploidentical stem cells refer to an investigational adoptive immunotherapy protocol developed at Weill Medical College of Cornell University for the treatment of high-risk acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This cellular therapy involves the infusion of hematopoietic stem cells (specifically CD34+ cells) collected from a half-matched (haploidentical) related donor, such as a parent, child, or sibling. Administered following induction or salvage chemotherapy, these cells are intended to exert a graft-versus-leukemia (GVL) effect, where the donor's immune system recognizes and attacks residual malignant cells. The therapy also aims to accelerate hematopoietic recovery after intensive chemotherapy and serves as a bridge to a subsequent formal allogeneic hematopoietic stem cell transplant.
- Other names
- haplo-identical cellshaploidentical donor cellshaploidentical cell infusionhaplo-identical cells (donor)
Beyond the preview
Go deeper on haploidentical stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haploidentical stem cells.